Navigation Links
VaxGen Files 2006 Financial Statements and Provides Cash Update
Date:8/30/2007

SOUTH SAN FRANCISCO, Calif., Aug. 30 /PRNewswire-FirstCall/ -- VaxGen, Inc. (Pink Sheets: VXGN) announced today that it has filed with the Securities and Exchange Commission (SEC) its Annual Report on Form 10-K for the year ended December 31, 2006 and Quarterly Reports on Form 10-Q for the first three quarters of 2006. The reports can be found at the link titled "SEC Filings" in the Investor Relations section of VaxGen's web site at http://www.vaxgen.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO)

The only financial statements the company has outstanding before it regains compliance with its SEC financial reporting obligations are the Quarterly Reports on Form 10-Q for the quarters ended March 31 and June 30, 2007, both of which are under review by VaxGen and its independent auditors. Once VaxGen is current with its financial statements, the company intends to apply for listing on a national stock exchange.

VaxGen's estimated cash, cash equivalents and short-term investments totaled $85.7 million as of the end of the company's most recent quarter on June 30, 2007.

VaxGen, Inc. is a biopharmaceutical company located in South San Francisco. For more information, please visit the company's web site at http://www.vaxgen.com.

Note: This press release contains "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the anticipated filing of the company's outstanding quarterly reports and its application for listing of its common stock. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Readers are cautioned not to place undue reliance on t
'/>"/>

SOURCE VaxGen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. PCR Polymerases Application Profiles
2. RNAlater Preserves Bacterial Gene Expression Profiles for Array Analysis
3. Obtaining a contour map from multifiles or 3D data in DataMax
4. Successful stabilization of gene expression profiles
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Third Wave files countersuit vs. Digene in patent case
7. TomoTherapy files registration statement for IPO
8. Merge files financial reports by market opening
9. The Why Files celebrates decade of science exploration
10. Third Wave files patent suits against Digene, Chiron and Bayer
11. New Web virus could lead to lost files, extortion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 21, 2013  MacroGenics, Inc. today announced that ... (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in ... oncoprotein," will be presented at the 2013 Annual ... during the Developmental Therapeutics - Immunotherapy Oral Abstract ... 4:30 PM.  The presentation will describe the results ...
(Date:5/21/2013)... NY (PRWEB) May 21, 2013 Bed bugs ... according to My Cleaning Products, many turn to chemical-based pesticides ... of the health and environmental risks those solutions present, the ... with Bed Bug Bully instead. , According to My ... bugs as they used to be. It shared that the ...
(Date:5/21/2013)... Ontario (PRWEB) May 21, 2013 ... scientists of the ITN to design the study, ... of two key clinical models used in the ... (EEC) and Nasal Allergen Challenge (NAC) models. Although ... by numerous publications, to date no direct comparison ...
(Date:5/21/2013)... SoundConnect is pleased to announce the release ... in Canada. Lync is the next generation of ... and organizations to collaborate and communicate much more easily ... the United States. With the progressive rollout of Lync ... Canada, SoundConnect now offers a complete Microsoft Lync solution ...
Breaking Biology Technology:MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2SoundConnect Announces Microsoft Lync Release in Canada 2SoundConnect Announces Microsoft Lync Release in Canada 3
... Calif. and BANGALORE, India, July 10, 2011 Life ... that it has launched a regional distribution hub in India ... The new India Distribution Center (IDC), located ... of Life Technologies, products to its thousands of customers in ...
... NATICK, Mass., July 8, 2011 RegenoCELL Therapeutics, Inc. (OTCBB: ... pleased to announce the opening of another state of the ... congestive heart failure and peripheral artery disease with its autologous ... congestive heart failure is administered at the Metropolitan Hospital in ...
... Care Compliance Strategies, Inc. (HCCS) announced today a partnership ... to deliver a series of critical care nursing and ... Management Systems.  This training includes two separate AACN courses: ... Essentials of Nurse Manager Orientation . The courses ...
Cached Biology Technology:Life Technologies Launches New Distribution Center in India 2Life Technologies Launches New Distribution Center in India 3RegenoCELL Announces That Patients Can Be Treated With Its Autologous Stem Cell Therapy in Greece 2RegenoCELL Announces That Patients Can Be Treated With Its Autologous Stem Cell Therapy in Greece 3HCCS Partners with American Association of Critical Care Nurses (AACN) to Offer Nurse Training 2HCCS Partners with American Association of Critical Care Nurses (AACN) to Offer Nurse Training 3
(Date:5/20/2013)... MINNEAPOLIS/ST. PAUL (MAY 20, 2013) University of Minnesota ... of Minnesota, in partnership with the University,s Brain Tumor ... peripheral nerve sheath tumors (MPNST) that allow them to ... of cancer. , The research was published this week ... the Sleeping Beauty transposon method, researchers in the lab ...
(Date:5/20/2013)... New research suggests that a compound abundant in the ... death. , By altering a very specific step ... into normal cells that die as scheduled. , One ... process that would cause them to die on a ... study in cells, led by Ohio State University researchers, ...
(Date:5/20/2013)... study conducted at the University of Bristol and published ... sheds light on how the brain and inner ... Bristol,s School of Earth Sciences, together with Tom Hbner ... brains of 150 million year old dinosaurs. , The ... Dysalotosaurus lettowvorbecki : a very young (juvenile) individual ...
Breaking Biology News(10 mins):U of M researchers develop model for better testing, targeting of MPNST 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 3Fossil brain teaser 2
... University of Santiago de Compostela (USC) have studied the ... show that the principal goal of young people is ... antisocial among them place greater importance on popularity with ... on are to do with leaving home, work and ...
... ulcers, one of the ,neglected tropical diseases, left aside by ... in poor regions. But then more attention has to be ... rules of the World Health Organization urgently need to be ... Medicine (ITM), based on ten years of research in Congo. ...
... This release is available in Spanish . ... receive--in addition to what foods you eat--all can influence the ... for optimum health. In a preliminary and apparently first-of-its-kind study, ... colleagues have developed a preliminary model that predicts an individual,s ...
Cached Biology News:Teenagers want to finish their studies and leave home 2WHO guidelines on Buruli ulcer need adjustment 2Model predicts individual's vitamin D needs 2
... 10X BlueJuice Gel Loading ... easy loading and tracking ... agarose or native polyacrylamide ... features higher density sucrose ...
... 3F10B10. Immunogen: Synthetic peptide ... of JAB1 (Jun activation domain-binding ... Specific for the JAB1 protein. ... 293T Jurkat cell lysates). ...
... TOPO Cloning is ... available for cloning PCR ... and Zero Blunt TOPO ... and activated with topoisomerase ...
... Conjugated peptides or recombinant proteins are ... produce antibodies in 2 rabbits. pre-immune and ... test until the titer reaches 1:4,000 Western ... Protein G purification Antibodies are eluted using ...
Biology Products: